Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

The investigators determined which antibody was best able to specifically bind the fusion protein. They used this antibody to compare the amounts of freestanding BTLA and HVEM and their protein ...

These strategies include biologic agents that deplete B cells by targeting cell-surface proteins such as CD19 or ... that disable the neonatal Fc receptor (FcRn), which protects IgG from ...

Belfast firm to partner with QUB to develop humanised therapeutic antibody to combat treatment-resistant cancers ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 ...

ESC Heart Failure 2025 Presentation Details (being held in Belgrade, Serbia, May 17-20, 2025): About TX45, a long-acting Fc-relaxin fusion protein TX45 is ... and development of therapeutic proteins ...

About IBI363 (First-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein) IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 ...